Abstract
Patients with cholangiocarcinoma (CC) have a poor prognosis, and their postoperative survival depends on cancer progression and recurrence. Thus, prognostic markers are needed. The fibrin cleavage product, D-dimer, is associated with malignant progression and recurrence in various cancers, and platelets also are related to tumor progression. This study therefore evaluated a new prognostic factor, D-dimer platelet multiplication (PDM), for predicting prognosis in cases of CC. This study retrospectively evaluated 55 cases to determine the correlations of D-dimer, platelet, and PDM levels with patient survival. The cutoff values for D-dimer, platelets, and PDM levels were determined using receiver operating characteristic curve analyses. The recurrence group exhibited significantly higher D-dimer (P=0.00075) and PDM (P=0.0000683) levels and a trend toward higher platelet levels (P=0.117). The optimal cutoff values were 1.3µg/mL for D-dimer levels, 245×104/µL for platelet levels, and 158.2×104µg/mL×µL for PDM levels. Poor recurrence-free survival was associated with high D-dimer levels (P=0.0428), high platelet levels (P=0.0498), and high PDM levels (P=0.00511). Poor cancer-specific survival was associated with high platelet levels (P=0.0156) and high PDM levels (P=0.0156). In the multivariate analysis, PDM had the greatest correlation with CC prognosis and independently predicted recurrence (P=0.00649). High D-dimer, platelet, and PDM levels were associated with poor recurrence-free and cancer-specific survivals, with PDM exhibiting the greatest correlation with prognosis. Therefore, PDM may help to predict recurrence and prognosis for patients with CC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.